comparemela.com

விரிவான மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials

Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials ·         Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Wee.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.